Streetbeat News

Regulatory

MIRA

MIRA Pharmaceuticals reports that its oral ketamine analog, Ketamir-2, has shown greater efficacy than FDA-approved treatments Gabapentin and Pregabalin in preclinical models of neuropathic pain. The company is conducting further studies and plans to submit an IND application by the end of 2024, with Phase I trials in Q1 2025.

Portfolio Pulse from Benzinga Newsdesk

October 21, 2024 | 11:10 am

PYPD

PolyPid published a full dataset from its first Phase 3 study of D-PLEX100 in the International Journal of Surgery. The SHIELD I study, one of the largest in over a decade for SSI prevention in colorectal resection, showed potential benefits for high-risk patients. The ongoing SHIELD II study focuses on large surgical incisions, with results expected in Q1 2025.

Portfolio Pulse from Benzinga Newsdesk

October 21, 2024 | 11:08 am

ACXP

Acurx Pharmaceuticals presented a scientific poster at IDWeek 2024, highlighting ibezapolstat's potential benefits for C. difficile Infection (CDI). The company is advancing ibezapolstat into international Phase 3 trials and preparing regulatory submissions in the EU, UK, Japan, and Canada. The drug has FDA QIDP and Fast-Track Designation.

Portfolio Pulse from Benzinga Newsdesk

October 21, 2024 | 11:06 am

ARQT

Health Canada has approved Arcutis' Zoryve (Roflumilast Foam 0.3%) for the treatment of seborrheic dermatitis in patients aged 9 and older. This approval marks a significant milestone for Arcutis, potentially expanding its market reach and revenue opportunities.

Portfolio Pulse from Benzinga Newsdesk

October 21, 2024 | 11:04 am

GOEV

Canoo has received IVA regulatory certificates for its right-hand drive electric commercial delivery vans in the UK, meeting national technical requirements.

Portfolio Pulse from Benzinga Newsdesk

October 21, 2024 | 11:01 am

COIN

Coinbase CEO Brian Armstrong and Elon Musk have endorsed John Deaton, a pro-cryptocurrency candidate, in the Massachusetts Senate race against Elizabeth Warren. Armstrong criticized Warren's anti-crypto stance, while Musk's endorsement aligns with his political views.

Portfolio Pulse from Aniket Verma

October 21, 2024 | 11:01 am

VVI

Viad Corp has entered into a definitive agreement to sell its GES business to Truelink Capital for $535 million. The deal is expected to close by the end of 2024, pending regulatory approvals and customary conditions. This transaction will separate GES from Viad's Pursuit attractions and hospitality business.

Portfolio Pulse from Benzinga Newsdesk

October 21, 2024 | 10:56 am

ZYME

ZymeWorks has initiated a Phase 1 trial for ZW171, targeting advanced MSLN-expressing cancers, including ovarian cancer and NSCLC. The study will assess safety, tolerability, and anti-tumor activity across multiple cohorts.

Portfolio Pulse from Benzinga Newsdesk

October 21, 2024 | 10:04 am

BGNE

The European Medicines Agency's Committee for Medicinal Products for Human Use has issued positive opinions recommending extended authorization for BeiGene's Tevimbra (Tislelizumab) for certain types of cancer.

Portfolio Pulse from Benzinga Newsdesk

October 21, 2024 | 10:01 am

INTC

TSLA

TSM

Tesla and Intel have denied allegations by China's Ministry of State Security of illegal mapping activities and espionage. The accusations come amid rising US-China tensions, particularly in the tech sector. Tesla and Intel emphasize their compliance with local laws.

Portfolio Pulse from Benzinga Neuro

October 21, 2024 | 9:19 am